Haloperidol-induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies.

Aamir, Y. K., Aijaz, A. S., Ghulam, A. M., & Patole, A. M. (2017). Evaluation of protective role of N-methyl-D-aspartate receptor antagonist against Parkinson’s model(s) in rat. International Journal of Green Pharmacy, 11(4), 803-808. http://dx.doi.org/10.22377/ijgp.v11i04.1362.

Abdel-Salam, O. M., & Baiuomy, A. R. (2007). Effect of different drugs influencing monoamine neurotransmission on haloperidol-induced catalepsy in mice. Turkish Journal of Medical Sciences, 37(6), 333-338. https://dergipark.org.tr/en/pub/tbtkmedical/issue/12325/147712.

Abdel-Salam, O. M. E., El-Shamarka, M. E. S., Salem, N. A., & Gaafar, A. E. D. M. (2012). Effects of Cannabis sativa extract on haloperidol-induced catalepsy and oxidative stress in the mice. EXCLI Journal, 11, 45-58. https://doi.org/www.ncbi.nlm.nih.gov/pmc/articles/PMC4928014/pdf/EXCLI-11-45.pdf.

Acuña-Lizama, M. M., Bata-García, J. L., Alvarez-Cervera, F. J., & Góngora-Alfaro, J. L. (2013). Caffeine has greater potency and efficacy than theophylline to reverse the motor impairment caused by chronic but not acute interruption of striatal dopaminergic transmission in rats. Neuropharmacology, 70, 51-62. https://doi.org/10.1016/j.neuropharm.2013.01.002

Adedeji, H. A., Ishola, I. O., & Adeyemi, O. O. (2014). Novel action of metformin in the prevention of haloperidol-induced catalepsy in mice: Potential in the treatment of Parkinson's disease? Progress in Neuro-Psychopharmacology and Biological Psychiatry, 48, 245-251. https://doi.org/10.1016/j.pnpbp.2013.10.014

Aghasadeghi, M. R., Siadat, S. D., Ardestani, M. S., Arabzadeh, A. J., Elmi, M., & Moghaddam, H. F. (2012). Selective cyclooxygenase-2 inhibitor compound 11b improves haloperidol-induced catatonia by enhancing the striatum dopaminergic neurotransmission. Iranian Journal of Pharmaceutical Research, 11(1), 339-345. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813089/pdf/ijpr-11-339.pdf.

Ahemad, R. S., Venkataraman, K. N., Jayaveera, F., Mohammed, A., Mohammed, I., & Krishna, Y. (2009). Effect of hydro-alcoholic root extract of ardostachys jatamansi on haloperidol induced parkinsonism in wistar rats. Pharmacologyonline, 2, 1145-1154.

Ahmadi, S. A., Sabahi, M. M., & Haddadi, R. (2018). The preventive/protective effect of testosterone on haloperidol-induced extrapyramidal disorders in male rats. Journal of Babol University of Medical Sciences, 20(7), 55-62.

Ahmadi, S. A., Sabahi, M., & Haddadi, R. (2019). The effect of acute and repeated administration of buspirone, 8-OHDPAT and fluoxetine on haloperidol-induced extrapyramidal symptoms. Neuropsychopharmacol Hung, 21(2), 59-68. https://pubmed.ncbi.nlm.nih.gov/31378723/.

Alvarez-Cervera, F. J., Villanueva-Toledo, J., Moo-Puc, R. E., Heredia-López, F. J., Alvarez-Cervera, M., Pineda, J. C., & Góngora-Alfaro, J. L. (2005). A novel automated rat catalepsy bar test system based on a RISC microcontroller. Journal of Neuroscience Methods, 146(1), 76-83. https://doi.org/10.1016/j.jneumeth.2005.01.018

Antelman, S. M., Kocan, D., Edwards, D. J., Knopf, S., Perel, J. M., & Stiller, R. (1986). Behavioral effects of a single neuroleptic treatment grow with the passage of time. Brain Research, 385(1), 58-67. https://doi.org/10.1016/0006-8993(86)91547-7

Antkiewicz-Michaluk, L., Michaluk, J., Romańska, I., Papla, I., & Vetulani, J. (2000). Antidopaminergic effects of 1,2,3,4-tetrahydroisoquinoline and salsolinol. Journal of Neural Transmission, 107, 1009-1019. https://doi.org/10.1007/s007020070049

Araki, T., Mizutani, H., Matsubara, M., Imai, Y., Mizugaki, M., & Itoyama, Y. (2001). Nitric oxide synthase inhibitors cause motor deficits in mice. European Neuropsychopharmacology, 11(2), 125-133. https://doi.org/10.1016/S0924-977X(01)00077-3

Ardashov, O. V., Pavlova, A. V., Il’ina, I. V., Morozova, E. A., Korchagina, D., Karpova, E. V., Volcho, K. P., Tolstikova, T. G., & Salakhutdinov, N. F. (2011). Highly potent activity of (1R, 2R, 6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in animal models of Parkinson’s disease. Journal of Medicinal Chemistry, 54(11), 3866-3874. https://doi.org/10.1021/jm2001579

Ardayfio, P. A., Leung, A., Park, J., Hwang, D.-Y., Moran-Gates, T., Choi, Y. K., Carlezon, W. A. Jr, Tarazi, F. I., & Kim, K. S. (2010). Pitx3-Deficient Aphakia mice display unique behavioral responses to psychostimulant and antipsychotic drugs. Neuroscience, 166(2), 391-396. https://doi.org/10.1016/j.neuroscience.2009.12.033

Atack, J. R., Shook, B. C., Rassnick, S., Jackson, P. F., Rhodes, K., Drinkenburg, W. H., Ahnaou, A., te Riele, P., Langlois, X., Hrupka, B., De Haes, P., Hendrickx, H., Aerts, N., Hens, K., Wellens, A., Vermeire, J., & Megens, A. A. H. P. (2014). JNJ-40255293, a novel adenosine A2A/A1 antagonist with efficacy in preclinical models of Parkinson’s disease. ACS Chemical Neuroscience, 5(10), 1005-1019. https://doi.org/10.1021/cn5001606

Azam, F. (2009). Synthesis of some urea and thiourea derivatives of naphtha[1,2-d]thiazol-2-amine as anti-Parkinsonian agents that cause neuroprotection against haloperidol-induced oxidative stress in mice. Medicinal Chemistry Research, 18(4), 287-308. https://doi.org/10.1007/s00044-008-9127-y

Azam, F., Alkskas, I. A., & Ahmed, M. A. (2009). Synthesis of some urea and thiourea derivatives of 3-phenyl/ethyl-2-thioxo-2,3-dihydrothiazolo[4,5-d]pyrimidine and their antagonistic effects on haloperidol-induced catalepsy and oxidative stress in mice. European Journal of Medicinal Chemistry, 44(10), 3889-3897. https://doi.org/10.1016/j.ejmech.2009.04.007

Azam, F., Barodia, S. K., Anwer, T., & Alam, M. M. (2009). Neuroprotective effect of naphtha[1,2-d]thiazol-2-amine in an animal model of Parkinson's disease. Journal of Enzyme Inhibition and Medicinal Chemistry, 23(3), 808-817. https://doi.org/10.1080/14756360802399183

Azam, F., El-gnidi, B. A., Alkskas, I. A., & Ahmed, M. A. (2010). Design, synthesis and anti-Parkinsonian evaluation of 3-alkyl/aryl-8-(furan-2-yl)thiazolo [5,4-e][1,2,4]triazolo[1,5-c]pyrimidine-2(3H)-thiones against neuroleptic-induced catalepsy and oxidative stress in mice. Journal of Enzyme Inhibition and Medicinal Chemistry, 25(6), 818-826. https://doi.org/10.3109/14756361003671052

Azam, F., Prasad, M. V. V., Thangavel, N., Shrivastava, A. K., & Mohan, G. (2012). Structure-based design, synthesis and molecular modeling studies of thiazolyl urea derivatives as novel anti-parkinsonian agents. Medicinal Chemistry, 8(6), 1057-1068. https://doi.org/10.2174/1573406411208061057

Banerjee, A., Patil, S., Pawar, M. Y., Gullapalli, S., Gupta, P. K., Gandhi, M. N., Bhateja, D. K., Bajpai, M., Sangana, R. R., Gudi, G. S., Khairatkar-Joshi, N., & Gharat, L. A. (2012). Imidazopyridazinones as novel PDE7 inhibitors: SAR and in vivo studies in Parkinson’s disease model. Bioorganic & Medicinal Chemistry Letters, 22(19), 6286-6291. https://doi.org/10.1016/j.bmcl.2012.07.077

Barodia, S. K., Mishra, C. B., Prakash, A., Kumar, J. B. S., Kumari, N., & Luthra, P. M. (2011). Novel 8-(furan-2-yl)-3-benzyl thiazolo [5,4-e][1,2,4] triazolo [1,5-c] pyrimidine-2(3H)-thione as selective adenosine A2A receptor antagonist. Neuroscience Letters, 488(1), 1-5. https://doi.org/10.1016/j.neulet.2010.08.006

Barré-Sinoussi, F., & Montagutelli, X. (2015). Animal models are essential to biological research: Issues and perspectives. Future Science OA, 1(4), FSO63. https://doi.org/10.4155/fso.15.63

Barroca, N. C. B., Guarda, M. D., da Silva, N. T., Colombo, A. C., Reimer, A. E., Brandão, M. L., & de Oliveira, A. R. (2019). Influence of aversive stimulation on haloperidol-induced catalepsy in rats. Behavioural Pharmacology, 30(2-3), 229-238. https://doi.org/10.1097/FBP.0000000000000462

Basu, S., Barawkar, D., Ramdas, V., Naykodi, M., Shejul, Y., Patel, M., Thorat, S., Panmand, A., Kashinath, A., Bonagiri, R., Prasad, V., Bhat, G., Quraishi, A., Chaudhary, S., Magdum, A., Meru, A. V., Gosh, I., Bhamidipati, R., Raje, A., … Mookhtiar, K. A. (2017). Discovery of potent and selective A2A antagonists with efficacy in animal models of Parkinson’s disease and depression. ACS Medicinal Chemistry Letters, 8(8), 835-840.

Bateup, H. S., Santini, E., Shen, W., Birnbaum, S., Valjent, E., Surmeier, D. J., Fisone, G., Nestler, E. J., & Greengard, P. (2010). Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proceedings of the National Academy of Sciences of the United States of America, 107(33), 14845-14850. https://doi.org/10.1073/pnas.1009874107

Belzung, C., & Lemoine, M. (2011). Criteria of validity for animal models of psychiatric disorders: Focus on anxiety disorders and depression. Biology of Mood & Anxiety Disorders, 1(9), 1-14. https://doi.org/10.1186/2045-5380-1-9

Bennouar, K. E., Uberti, M. A., Melon, C., Bacolod, M. D., Jimenez, H. N., Cajina, M., Goff, L. K. L., Doller, D., & Gubellini, P. (2013). Synergy between l-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: Implications for Parkinson's disease treatment and dyskinesia. Neuropharmacology, 66, 158-169. https://doi.org/10.1016/j.neuropharm.2012.03.022

Betarbet, R., Sherer, T. B., & Greenamyre, J. T. (2002). Animal models of Parkinson's disease. BioEssays, 24(4), 308-318. https://doi.org/10.1002/bies.10067

Beurrier, C., Lopez, S., Révy, D., Selvam, C., Goudet, C., Lhérondel, M., Gubellini, P., Goff, L. K. L., Acher, F., Pin, J. P., & Amalric, M. (2009). Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. Faseb Journal, 21(10), 3619-3628. https://doi.org/10.1096/fj.09-131789

Bhangale, J. O., & Acharya, S. R. (2016). Anti-parkinson activity of petroleum ether extract of ficus religiosa (L.) leaves. Advances in Pharmacological and Pharmaceutical Sciences, 2016, 1-9. https://doi.org/10.1155/2016/9436106

Bhattamisra, S. K., Shak, A. T., Xi, L. W., Safian, N. H., Choudhury, H., Lim, W. M., Shahzad, N., Alhakamy, N. A., Anwer, M. K., Radhakrishnan, A. K., & Md, S. (2020). Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson’s disease. International Journal of Pharmaceutics, 579, 119148. https://doi.org/10.1016/j.ijpharm.2020.119148

Björklund, A., & Dunnett, S. B. (2007). Dopamine neuron systems in the brain: An update. Trends in Neurosciences, 30(5), 194-202. https://doi.org/10.1016/j.tins.2007.03.006

Bollinger, S. R., Engers, D. W., Panarese, J. D., West, M., Engers, J. L., Loch, M. T., Rodriguez, A. L., Blobaum, A. L., Jones, C. K., Gray, A. T., Conn, P. J., Lindsley, C. W., Niswender, C. M., & Hopkins, C. R. (2019). Discovery, structure-activity relationship, and biological characterization of a novel Series of 6-((1H-Pyrazolo[4,3-b]pyridin-3-yl)amino)-benzo[d]isothiazole-3-carboxamides as positive allosteric modulators of the metabotropic glutamate receptor 4 (mGlu4). Journal of Medicinal Chemistry, 62(1), 342-358. https://doi.org/10.1021/acs.jmedchem.8b00994

Bradley, S. R., Marino, M. J., Wittmann, M., Rouse, S. T., Awad, H., Levey, A. I., & Conn, P. J. (2000). Activation of Group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia nigra pars reticulata. Journal of Neuroscience, 20(9), 3085-3094. https://doi.org/10.1523/JNEUROSCI.20-09-03085.2000

Breysse, N., Baunez, C., Spooren, W., Gasparini, F., & Amalric, M. (2002). Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. The Journal of Neuroscience, 22(13), 5669-5678. https://doi.org/10.1523/JNEUROSCI.22-13-05669.2002

Cannella, M., Motolese, M., Bucci, D., Molinaro, G., Gradini, R., Bruno, V., Nicoletti, N., & Battaglia, G. (2015). Changes in the expression of genes encoding for mGlu4 and mGlu5 receptors and other regulators of the indirect pathway in acute mouse models of drug-induced parkinsonism. Neuropharmacology, 95, 50-58. https://doi.org/10.1016/j.neuropharm.2015.02.024

Celorrio, M., Fernández-Suárez, D., Rojo-Bustamante, E., Echeverry-Alzate, V., Ramírez, M. G., Hillard, C. J., López-Moreno, J. A., Maldonado, R., Oyarzábal, J., Franco, R., & Aymerich, M. S. (2016). Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson’s disease. Brain, Behavior and Immunity, 57, 94-105. https://doi.org/10.1016/j.bbi.2016.06.010

Celorrio, M., Rojo-Bustamante, E., Fernández-Suárez, D., Sáez, E., de Mendoza, A. E. H., Müller, C. E., Ramírez, M. J., Oyarzábal, J., Franco, R., & Aymerich, M. S. (2017). GPR55: A therapeutic target for Parkinson’s disease? Neuropharmacology, 125, 319-332. https://doi.org/10.1016/j.neuropharm.2017.08.017

Charvin, D., Pomel, V., Ortiz, M., Frauli, M., Scheffler, S., Steinberg, E., Baron, L., Deshons, L., Rudigier, R., Thiarc, D., Morice, C., Manteau, B., Mayer, S., Graham, D., Giethlen, B., Brugger, N., Hédou, G., Conquet, F., & Schann, S. (2017). Discovery, structure-activity relationship, and antiparkinsonian effect of a potent and brain-penetrant chemical series of positive allosteric modulators of metabotropic glutamate receptor 4. Journal of Medicinal Chemistry, 60(20), 8515-8537. https://doi.org/10.1021/acs.jmedchem.7b00991

Chaudhary, P., & Dhande, S. (2020). Evaluation of anti-Parkinson’s activity of ethanolic extract of Tridax procumbens (Asteraceae). Indian Journal of Natural Products and Resources, 11(1), 9-17.https://doi.org/http://nopr.niscair.res.in/handle/123456789/54489.

Chitra, V., Manasa, K., Mythili, A., Tamilanban, T., & Gayathri, K. (2017). Effect of hydroalcoholic extract of achyranthes aspera on haloperidol induced parkinson’s disease in wistar rats. Asian Journal of Pharmaceutical and Clinical Research, 10(9), 318-321. https://doi.org/10.22159/ajpcr.2017.v10i9.19285

Chiu, S., Paulose, C. S., & Mishra, R. K. (1981). Effect of L-prolyl-L-leucyl-glycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor bindings. Peptides, 2(1), 105-111. https://doi.org/10.1016/S0196-9781(81)80019-8

Chopde, C. T., Hote, M. S., Mandhane, S. N., & Muthal, A. V. (1995). Glucocorticoids attenuate haloperidol induced catalepsy through adrenal catecholamines. Journal of Neural Transmission, 102(1), 47-54. https://doi.org/10.1007/BF01276564

Ciucci, M. R., & Connor, N. P. (2009). Dopaminergic influence on rat tongue function and limb movement initiation. Experimental Brain Research, 194(4), 587-596. https://doi.org/10.1007/s00221-009-1736-2

Clark, C. A. M., Sacrey, L. A. R., & Whishaw, I. Q. (2009). Righting elicited by novel or familiar auditory or vestibular stimulation in the haloperidol-treated rat: Rat posturography as a model to study anticipatory motor control. Journal of Neuroscience Methods, 182(2), 266-271. https://doi.org/10.1016/j.jneumeth.2009.06.017

Collins, L. E., Sager, T. N., Sams, A. G., Pennarola, A., Port, R. G., Shahriari, M., & Salamone, J. D. (2012). The novel adenosine A(2A) antagonist Lu AA47070 reverses the motor and motivational effects produced by dopamine D2 receptor blockade. Pharmacology Biochemistry and Behavior, 100(3), 498-505. https://doi.org/10.1016/j.pbb.2011.10.015

Colombo, A. C., de Oliveira, A. R., Reimer, A. E., & Brandão, M. L. (2013). Dopaminergic mechanisms underlying catalepsy, fear and anxiety: Do they interact? Behavioural Brain Research, 257, 201-207. https://doi.org/10.1016/j.bbr.2013.10.002

Cortés, M., Malave, L., Castello, J., Flajolet, M., Cenci, M. A., Friedman, E., & Rebholz, H. (2017). CK2 oppositely modulates L-DOPA-induced dyskinesia via striatal projection neurons expressing D1 or D2 receptors. The Journal of Neuroscience, 37(49), 11930-11946. https://doi.org/10.1523/JNEUROSCI.0443-17.2017

Costain, W. J., Buckley, A. T., Evans, M. C., Mishra, R. K., & Johnson, R. L. (1999). Modulatory effects of PLG and its peptidomimetics on haloperidol-induced catalepsy in rats. Peptides, 20(6), 761-767. https://doi.org/10.1016/s0196-9781(99)00060-1

Dagaev, S. G., Filko, O. A., Kubarskaya, L. G., Khrabrova, A. V., Mukovskii, L. A., Glukhova, R. I., Sanotskii, V. I., & Dolgo-Saburov, V. B. (2004). Effect of M2 muscarinic receptor blockade in rats with haloperidol-produced catatonic syndrome. Bulletin of Experimental Biology and Medicine, 137(5), 468-470. https://doi.org/10.1023/b:bebm.0000038155.56296.50

Danysz, W., Gossel, M., Zajaczkowski, W., Dill, D., & Quack, G. (1994). Are NMDA antagonistic properties relevant for antiparkinsonianlike activity in rats? - Case of amantadine and memantine. Journal of Neural Transmission, 7(3), 155-166. https://doi.org/10.1007/BF02253435

Dar, P. A., Parray, S. A., Sofi, G., & Jafri, M. A. (2012). Catalepsy, a scientific model for exploring unani herbs having possible specificity for different neurotransmitters: A review. American Journal of Pharmatech Research, 2(6), 177-186. http://ajptr.com/archive/volume-2/december-2012-issue-6.

Darbaky, Y., Forni, C., Amalric, M., & Baunez, C. (2003). High frequency stimbarrolation of the subthalamic nucleus has beneficial antiparkinsonian effects on motor functions in rats, but less efficiency in a choice reaction time task. European Journal of Neuroscience, 18(4), 951-956. https://doi.org/10.1046/j.1460-9568.2003.02803.x

Dawson, T. M., Ko, H. S., & Dawson, V. L. (2010). Genetic animal models of Parkinson’s disease. Neuron, 66(5), 646-661. https://doi.org/10.1016/j.neuron.2010.04.034

De Ryck, M., Schallert, T., & Teitelbaum, P. (1980). Morphine versus haloperidol catalepsy in the rat; a behavioural analysis of postural support mechanisms. Brain Research, 201(1), 143-172. https://doi.org/10.1016/0006-8993(80)90781-7

De Ryck, M., & Teitelbaum, P. (1984). Morphine catalepsy as an adaptive reflex state in rats. Behavioral Neuroscience, 98(2), 243-261. https://doi.org/10.1037/0735-7044.98.2.243

Dekundy, A., Pietraszek, M., Schaefer, D., Cenci, M. A., & Danysz, W. (2006). Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson’s disease. Brain Research Bulletin, 69(3), 318-326. https://doi.org/10.1016/j.brainresbull.2005.12.009

Delfs, J. M., Ciaramitaro, V. M., Soghomonian, J. J., & Chesselet, M. F. (1996). Unilateral nigrostriatal lesions induce a bilateral increase in glutamate decarboxylase messenger RNA in the reticular thalamic nucleus. Neuroscience, 71(2), 383-395. https://doi.org/10.1016/0306-4522(95)00470-x

Denayer, T., Stohr, T., & Roy, M. V. (2014). Animal models in translational medicine: Validation and prediction. New Horizons in Translational Medicine, 2(1), 5-11. https://doi.org/10.1016/j.nhtm.2014.08.001

Dhingra, D., & Gahalain, N. (2016). Amelioration of haloperidol-induced orofacial dyskinesia and catalepsy by ellagic acid in rats. International Journal of Ayurveda and Pharma Research, 7(2), 222-227. https://doi.org/10.7897/2277-4343.07292

Dickson, D. W. (2012). Parkinson's disease and parkinsonism: Neuropathology. Cold Spring Harbor Perspectives in Medicine, 2(8), 1-15. https://doi.org/10.1101/cshperspect.a009258

Duty, S., & Jenner, P. (2011). Animal models of Parkinson’s diseases: A source of novel treatments and clues to the cause of the disease. British Journal of Pharmacology, 164(4), 1357-1391.

East, S. P., Bamford, S., Dietz, M. G. A., Eickmeier, C., Flegg, A., Ferger, B., Gemkow, M. J., Heilker, R., Hengerer, B., Kotey, A., Loke, P., Schänzle, G., Schubert, H. D., Scott, J., Whittaker, M., Williams, M., Zawadzki, P., & Gerlach, K. (2010). An orally bioavailable positive allosteric modulator of the mGlu4 receptor with efficacy in an animal model of motor dysfunction. Bioorganic & Medicinal Chemistry Letters, 20(16), 4901-4905. https://doi.org/10.1016/j.bmcl.2010.06.078

Egan, M. F., Ferguson, J. N., & Hyde, T. M. (1995). Effects of chronic naloxone administration on vacuous chewing movements and catalepsy in rats treated with long-term haloperidol decanoate. Brain Research Bulletin, 38(4), 355-363. https://doi.org/10.1016/0361-9230(95)00108-q

El Yacoubi, M., Ledent, C., Parmentier, M., Costentin, J., & Vaugeois, J. M. (2001). Adenosine A2A receptor knockout mice are partially protected against drug-induced catalepsy. NeuroReport, 12, 983-986. https://doi.org/10.1097/00001756-200104170-00024

Engelhardt, K. A., Marchetta, P., Schwarting, R. K. W., & Melo-Thomas, L. (2018). Haloperidol-induced catalepsy is ameliorated by deep brain stimulation of the inferior colliculus. Scientific Reports, 8, 2216. https://doi.org/10.1038/s41598-018-19990-y

Erosa-Rivero, H. B., Bata-García, J. L., Alvarez-Cervera, F. J., Heredia-López, F. J., & Góngora-Alfaro, J. L. (2014). The potency and efficacy of anticholinergics to inhibit haloperidol-induced catalepsy in rats correlates with their rank order of affinities for the muscarinic receptor subtypes. Neuropharmacology, 81, 176-187. https://doi.org/10.1016/j.neuropharm.2014.02.005

Fathi-Moghaddam, H., Ardestani, M. S., Saffari, M., Arabzadeh, A. J., & Elmi, M. (2010). The selective cyclooxygenase-2 inhibitor, the compound 11b improves haloperidol induced catatonia by enhancing the striatum dopaminergic neurotransmission. Iranian Journal of Pharmaceutical Research, 9(4), 387-393.

Ferger, B., Buck, K., Shimasaki, M., Koros, E., Voehringer, P., & Buerger, E. (2010). Continuous dopaminergic stimulation by pramipexole is effective to treat early morning akinesia in animal models of Parkinson’s disease: A pharmacokinetic-pharmacodynamic study using in vivo microdialysis in rats. Synapse (New York, N. Y.), 64(7), 533-541. https://doi.org/10.1002/syn.20759

Field, E. F., Whishaw, I. Q., & Pellis, S. M. (2000). Sex differences in catalepsy: Evidence for hormone-dependent postural mechanisms in haloperidol-treated rats. Behavioral Brain Research, 109(2), 207-212. https://doi.org/10.1016/s0166-4328(99)00174-6

Fink-Jensen, A., Schmidt, L. S., Dencker, D., Schulein, C., Wess, J., Wortwein, G., & Woldbye, D. P. D. (2011). Antipsychotic-induced catalepsy is attenuated in mice lacking the M4 muscarinic acetylcholine receptor. European Journal of Pharmacology, 656(1-3), 39-44. https://doi.org/10.1016/j.ejphar.2011.01.018

Fowler, S. C., & Mortell, C. (1992). Low doses of haloperidol interfere with rat tongue extensions during licking: A quantitative analysis. Behavioral Neuroscience, 106(2), 386-395. https://doi.org/10.1037//0735-7044.106.2.386

Frank, S. T., & Schmidt, W. J. (2003). Burst activity of spiny projection neurons in the striatum encodes superimposed muscle tetani in cataleptic rats. Experimental Brain Research, 152(4), 519-522. https://doi.org/10.1007/s00221-003-1644-9

Gamber, K. M. (2018). Animal Models of Parkinson’s Disease: New Models provide greater translational and predictive value. BioTechniques, 61(4), 210-211. https://doi.org/10.2144/000114463

Girdhari, L. G., & Avtar, C. R. (2009). Synergistic effect of Withania somnifera dunal and L-dopa in the inhibition of haloperidol-induced catalepsy in mice. Pharmacognosy, 5(9), 46-50.

Gmiro, V. E., Serdyuk, S. E., & Veselkina, O. S. (2015). Comparison of pharmacological potency and safety of glutamate blocker IEM-1913 and memantine. Bulletin of Experimental Biology and Medicine, 160(1), 68-71. https://doi.org/10.1007/s10517-015-3100-9

Golden, J. P., DeMaro, J. A., Knoten, A., Hoshi, M., Pehek, E., Johnson, E. M. Jr, Gereau, R. W. IV, & Jain, S. (2013). Dopamine-dependent compensation maintains motor behavior in mice with developmental ablation of dopaminergic neurons. The Journal of Neuroscience, 33(43), 17095-17107. https://doi.org/10.1523/JNEUROSCI.0890-13.2013

Gołembiowska, K., Dziubina, A., Kowalska, M., & Kamińska, K. (2009). Effect of adenosine A2A receptor antagonists on L-DOPA-induced hydroxyl radical formation in rat striatum. Neurotoxicity Research, 15(2), 155-166. https://doi.org/10.1007/s12640-009-9016-2

Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2013). Cannabidiol attenuates catalepsy induced by distinct pharmacological mechanisms via 5-HT1A receptor activation in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 46, 43-47.https://doi.org/10.1016/j.pnpbp.2013.06.005

Góngora-Alfaro, J. L., Moo-Puc, R. E., Villanueva-Toledo, J. R., Alvarez-Cervera, F. J., Bata-García, J. L., Heredia-López, F. J., & Pineda, J. C. (2009). Long-lasting resistance to haloperidol-induced catalepsy in male rats chronically treated with caffeine. Neuroscience Letters, 463(3), 210-214. https://doi.org/10.1016/j.neulet.2009.07.084

González-Lugo, O. E., Ceballos-Huerta, F., Jiménez-Capdeville, M. E., Arankowsky-Sandoval, G., & Góngora-Alfaro, J. L. (2010). Synergism of theophylline and anticholinergics to inhibit haloperidol-induced catalepsy: A potential treatment for extrapyramidal syndromes. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 34(8), 1465-1471. https://doi.org/10.1016/j.pnpbp.2010.08.003

Goudet, C., Vilar, B., Courtiol, T., Deltheil, T., Bessiron, T., Brabet, I., Oueslati, N., Rigault, D., Bertrand, H. O., McLean, H., Daniel, H., Amalric, M., Acher, F., & Pin, J. P. (2012). A novel selective metabotropic glutamate receptor 4 agonist reveals new possibilities for developing subtype selective ligands with therapeutic potential. Faseb Journal, 26, 1682-1693. https://doi.org/10.1096/fj.11-195941

Greco, B., Lopez, S., van der Putten, H., Flor, P. J., & Amalric, M. (2010). Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson’s disease. Journal Pharmacology and Experimental Therapeutics, 332(3), 1064-1071. https://doi.org/10.1124/jpet.109.162115

Greenbaum, L., Lifschytz, T., Zozulinsky, P., Broner, E. C., Slonimsky, A., Kohn, Y., & Lerer, B. (2012). Alteration in RGS2 expression level is associated with changes in haloperidol induced extrapyramidal features in a mutant mouse model. European Neuropsychopharmacology, 22(5), 379-386. https://doi.org/10.1016/j.euroneuro.2011.09.006

Gupta, B. K., Kumar, S., Kaur, H., Ali, J., & Baboota, S. (2017). Attenuation of oxidative damage by coenzyme Q10 loaded nanoemulsion through oral route for the management of Parkinson's disease. Rejuvenation Research, 21(3), 232-248.hppts://doi.org/10.1089/rej.2017.1959.

Hagino, Y., Kasai, S., Fujita, M., Setogawa, S., Yamaura, H., Yanagihara, D., Hashimoto, M., Kobayashi, K., Meltzer, H. Y., & Ikeda, K. (2015). Involvement of cholinergic system in hyperactivity in dopamine-deficient mice. Neuropsychopharmacology, 40(5), 1141-1150. https://doi.org/10.1038/npp.2014.295

Hamadjida, A., Nuara, S. G., Bédard, D., Frouni, I., Kwan, C., Gourdon, J. C., & Huot, P. (2018). Nefazodone reduces dyskinesia, but not psychosis-like behaviours, in the parkinsonian marmoset. Naunyn-schmiedeberg's Archives of Pharmacology, 391(12), 1339-1345. https://doi.org/10.1007/s00210-018-1549-6

Haraguchi, K., Ito, K., Kotaki, H., Sawada, Y., & Iga, T. (1997). Prediction of drug-induced catalepsy based on dopamine D1, D2, and muscarinic acetylcholine receptor occupancies. Drug Metabolism and Disposition, 25(6), 675-684. https://dmd.aspetjournals.org/content/25/6/675.long.

Haraguchi, K., Ito, K., Sawada, Y., & Iga, T. (1996). Catalepsy induced by manidipine, a calcium channel blocker, in mice. Journal of Pharmacy and Pharmacology, 48(4), 429-432. https://doi.org/10.1111/j.2042-7158.1996.tb05946.x

Hartgraves, S. L., & Kelly, P. H. (1984). Role of mesencephalic reticular formation in cholinergic-induced catalepsy d anticholinergic reversal of neuroleptic-induced catalepsy. Brain Research, 307(1-2), 47-54. https://doi.org/10.1016/0006-8993(84)90458-X.

Hille, C. J., Fox, S. H., Maneuf, Y. P., Crossman, A. R., & Brotchie, J. M. (2001). Antiparkinsonian action of a δ Opioid agonist in rodent and primate models of Parkinson’s disease. Experimental Neurology, 172(1), 189-198. https://doi.org/10.1006/exnr.2001.7763

Himori, N., Tanaka, Y., Kurasawa, M., Mishima, K., & Akaike, N. (1994). 3-0-Methyldopa attenuates the effects of madopar on the haloperidol induced cataleptic behavior and the locomotor activity in the mouse. Pharmacology, 48(4), 226-233. https://doi.org/10.1159/000139184

Hodgson, R. A., Bertorelli, R., Varty, G. B., Lachowicz, J. E., Forlani, A., Fredduzzi, S., Cohen-Williams, M. E., Higgins, G. A., Impagnatiello, F., Nicolussi, E., Parra, L. E., Foster, C., Zhai, Y., Neustadt, B. R., Stamford, A. W., Parker, E. M., Reggiani, A., & Hunter, J. C. (2009). Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7- [2- [4- models of movement disorders and depression. The Journal of Pharmacology and Experimental Therapeutics, 330(1), 294-303. https://doi.org/10.1124/jpet.108.149617

Hyde, T. M., Egan, M. F., Wing, L. L., Wyatt, R. J., Weinberger, D. R., & Kleinman, J. E. (1995). Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate. Psychopharmacology (Berl), 118(2), 142-149. https://doi.org/10.1007/BF02245832

Iderberg, H., Maslava, N., Thompson, A. D., Bubser, M., Niswender, C. M., Hopkins, C. R., Lindsley, C. W., Conn, P. J., Jones, C. K., & Cenci, M. A. (2015). Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and l-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. Neuropharmacology, 95, 121-129. https://doi.org/10.1016/j.neuropharm.2015.02.023

Iderberg, H., McCreary, A. C., Varney, M. A., Kleven, M. S., Koek, W., Bardin, L., Depoortère, R., Cenci, M. A., & Newman-Tancredi, A. (2015). NLX-112, a novel 5-HT 1A receptor agonist for the treatment of l -DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat. Experimental Neurology, 271, 335-350. https://doi.org/10.1016/j.expneurol.2015.05.021

Ingale, S. P., & Kasture, S. B. (2017). Protective effect of standardized extract of Passiflora incarnata flower in Parkinson's and Alzheimer's disease. Ancient Science of Life, 36(4), 200-206. https://doi.org/10.4103/asl.ASL_231_16

Invernizzi, R. W., Garavaglia, C., & Samanin, R. (2002). The alpha2-adrenoceptor antagonist idazoxan reverses catalepsy induced by haloperidol in rats independent of striatal dopamine release: Role of serotonergic mechanisms. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 28(5), 872-879. https://doi.org/10.1038/sj.npp.1300119.

Ionov, I. D., & Pushinskaya, I. I. (2013). Somatostatin antagonist induces catalepsy in the aged rat. Psychopharmacology (Berl), 227(2), 273-276. https://doi.org/10.1007/s00213-012-2961-0

Ionov, I. D., Pushinskaya, I. I., Gorev, N. P., & Frenkel, D. D. (2018). Cyclosomatostatin- and haloperidol-induced catalepsy in Wistar rats: Differential responsiveness to sleep deprivation. Neuroscience Letters, 684, 72-77.

Ionov, I. D., & Severtsev, N. N. (2012a). Somatostatin antagonist potentiates haloperidol-induced catalepsy in the aged rat. Pharmacology Biochemistry and Behavior, 103(2), 295-298. https://doi.org/10.1016/j.pbb.2012.08.006

Ionov, I. D., & Severtsev, N. N. (2012b). Histamine and haloperidol-induced catalepsy in aged mice: Differential responsiveness to L-DOPA. Psychopharmacology (Berl), 223(2), 191-197. https://doi.org/10.1007/s00213-012-2706-0

Ittiyavira, S. P., & Ruby, R. (2014). Effect of hydro-alcoholic root extract of Plumbago zeylanica l alone and its combination with aqueous leaf extract of Camellia sinensis on haloperidol induced parkinsonism in wistar rats. Annals Neurosciences, 21(2), 47-50. https://doi.org/10.5214/ans.0972.7531.210204

Jackson, J., Young, C. K., Hu, B., & Bland, B. H. (2008). High frequency stimulation of the posterior hypothalamic nucleus restores movement and reinstates hippocampal-striatal theta coherence following haloperidol-induced catalepsy. Experimental Neurology, 213(1), 210-219. https://doi.org/10.1016/j.expneurol.2008.06.007

Jackson-Lewis, V., Blesa, J., & Przedborski, S. (2012). Animal models of Parkinson’s disease. Parkinsonism & Related Disorders, 18, S183-S185. https://doi.org/10.1016/s1353-8020(11)70057-8

Jagmag, S. A., Tripathi, N., Shukla, S. D., Maiti, S., & Khurana, S. (2016). Evaluation of models of Parkinson’s disease. Frontiers in Neuroscience, 279(7), 1156-1166. https://doi.org/10.1111/j.1742-4658.2012.08491.x

Jagtap, A., & Inamdar, D. (2001). Study of antiparkinson’s activity of plain and niosomal pentoxifylline. Indian Journal of Pharmaceutical Sciences, 63(3), 239-243. https://www.ijpsonline.com/articles/study-of-antiparkinsons-activity-of-plain-and-niosomal-pentoxifylline.pdf.

Jankovic, J. (2008). Parkinson’s disease: Clinical features and diagnosis. Journal of Neurology, Neurosurgery and Psychiatry, 79(4), 368-376. https://doi.org/10.1136/jnnp.2007.131045

Jena, M., Mishra, S., Pal, A., & Mishra, S. S. (2014). Protective effect of Eclipta alba on haloperidol induced extrapyramidal movement disorders in albino rats. Journal of Chemical and Pharmaceutical Research, 6(7), 31-38. https://www.jocpr.com/articles/protective-effect-of-eclipta-alba-on-haloperidol-induced-extrapyramidal-movement-disorders-in-albino-rats.pdf.

Johnson, K. A., Jones, C. K., Tantawy, M. N., Bubser, M., Marvanova, M., Ansari, M. S., Baldwin, R. M., Conn, P. J., & Niswender, C. M. (2013). The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease. Neuropharmacology, 66, 187-195. https://doi.org/10.1016/j.neuropharm.2012.03.029

Jones, C. K., Bubser, M., Thompson, A. D., Dickerson, J. W., Turle-Lorenzo, N., Amalric, M., Blobaum, A. L., Bridges, T. M., Morrison, R. D., Jadhav, S., Engers, D. W., Italiano, K., Bode, J., Daniels, J. S., Lindsley, C. W., Hopkins, C. R., Conn, P. J., & Niswender, C. M. (2012). The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with l-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. Journal of Pharmacology and Experimental Therapeutics, 340(2), 404-421. https://doi.org/10.1124/jpet.111.187443

Jones, N., Bleickardt, C., Mullins, D., Parker, E., & Hodgson, R. (2013). A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats. Brain Research Bulletin, 98, 163-169. https://doi.org/10.1016/j.brainresbull.2013.07.001

Joshi, S. V., Bothara, S. B., & Surana, S. J. (2011). Evaluation of aqueous extract of Ocimum sanctum in experimentally induced parkinsonism. Journal of Chemical and Pharmaceutical Research, 3(1), 478-487. https://1library.net/document/zkev138z-evaluation-aqueous-extract-ocimum-sanctum-experimentally-induced-parkinsonism.html.

Joy, A. E., Shyamjith, M., & Bhat, S. K. (2012). Acute effect of ethanolic extract of moringa oleifera on haloperidol induced catalepsy in mice models. Drug Invention Today, 4(10), 543-545.

Juszkiewicz, M., Chodkowska, A., Burzynski, S. R., Mlynarczyk, M., & Kleinrok, Z. (1994). The influence of antineoplaston A5 on particular subtypes of central dopaminergic structures. Drugs under Experimental Clinical Research, 21(4), 153-156.

Juszkiewicz, M., Chodkowska, A., Burzynski, S. R., Mlynarczyk, M., & Kleinrok, Z. (1995). The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptors. Drugs under Experimental Clinical Research, 21, 153-156.

Kabra, A., Baghel, U. S., Hano, C., Martins, N., Khalid, M., & Sharma, R. (2020). Neuroprotective potential of Myrica esulenta in Haloperidol induced Parkinson’s disease. Journal of Ayurveda and Integrative Medicine, 11(4), 448-454. https://doi.org/10.1016/j.jaim.2020.06.007

Kalinina, A. P., Kapitsa, I. G., Ivanova, E. A., & Voronina, T. A. (2019). Antiparkinsonian action of the prolyl endopeptidase inhibitor in mice. Moscow University Biological Sciences Bulletin, 74(2), 69-74.

Kanda, T., Shiozaki, S., Shimada, J., Suzuki, F., & Nakamura, J. (1994). KF17837: A novel selective adenosine A2A receptor antagonist with anticataleptic activity. European Journal of Pharmacology, 256(3), 263-268. https://doi.org/10.1016/0014-2999(94)90551-7

Kapur, S., McClelland, R. A., VanderSpek, S. C., Wadenberg, M.-L., Baker, G., Nobrega, J., Zipursky, R. B., & Seeman, P. (2002). Increasing D2 affinity results in the loss of clozapineʼs atypical antipsychotic action. NeuroReport, 13(6), 831-835. https://doi.org/10.1097/00001756-200205070-00019

Karasawa, H., Taketo, M. M., & Matsui, M. (2003). Loss of anti-cataleptic effect of scopolamine in mice lacking muscarinic acetylcholine receptor subtype 4. European Journal of Pharmacology, 468(1), 15-19. https://doi.org/10.1016/s0014-2999(03)01642-x

Karcz-Kubicha, M., Lorenz, B., & Danysz, W. (1999). GlycineB antagonists and partial agonists in rodent models of Parkinson’s disease-Comparison with uncompetitive N-methyl-d-aspartate receptor antagonist. Neuropharmacology, 38(1), 109-119. https://doi.org/10.1016/S0028-3908(98)00165-8

Kasture, S., Barhate, S., Mohan, M., Ballero, M., Sanna, C., & Maxia, A. (2009). Caffeine withdrawal retains anticataleptic activity but Withania somnifera withdrawal potentiates haloperidol-induced catalepsy in mice. Natural Product Research, 23(8), 724-728. https://doi.org/10.1080/14786410802346215

Kasture, S. B., Mayur, G., Kasture, V., Sanjay, A., Balu, S., Rosas, M., Cotti, E., & Acquas, E. (2015). Tea component, epigallocatechin gallate, potentiates anticataleptic and locomotor-sensitizing effects of caffeine in mice. Behavioural Pharmacology, 26(1-2), 125-132. https://doi.org/10.1097/FBP.0000000000000071

Kasture, V. S., Suvarna, A. K., Mahajan, D., Wagh, R., Mohan, M., & Kasture, S. B. (2009). Antioxidant and antiparkinson activity of gallic acid derivatives. Pharmacologyonline, 1, 385-395.

Keeler, J. F., & Robbins, T. W. (2011). Translating cognition from animals to humans. Biochemical Pharmacology, 81, 1356-1366. https://doi.org/10.1016/j.bcp.2010.12.028

Kharkwal, G., Brami-Cherrier, K., Lizardi-Ortiz, J. E., Nelson, B. A., Ramos, M., Del Barrio, D., Sulzer, D., Kreitzer, C. A., & Borrelli, E. (2016). Parkinsonism driven by antipsychotics originates from dopaminergic control of striatal cholinergic interneurons. Neuron, 91(1), 67-78. https://doi.org/10.1016/j.neuron.2016.06.014

Kin, K., Yasuhara, T., Kameda, M., & Date, I. (2019). Animal models for Parkinson's disease research: Trends in the 2000s. International Journal of Molecular Sciences, 20(21), 5402. https://doi.org/10.3390/ijms20215402

Kinon, B. J., & Kane, J. M. (1989). Difference in catalepsy response in inbred rats during chronic haloperidol treatment is not predictive of the intensity of behavioral hypersensitivity which subsequently develops. Psychopharmacology (Berl), 98(4), 465-471. https://doi.org/10.1007/BF00441943

Kinoshita, H., Hasegawa, T., Katsumata, Y., Kameyama, T., Yamamoto, I., & Nabeshima, T. (1994). Effect of dizocilpine (MK-801) on the catalepsy induced by A9-tetrahydrocannabinol in mice. Journal of Neural Transmission, 95(2), 137-143. https://doi.org/10.1007/BF01276432

Kiselev, A. V., Vedenkin, A. S., Stovbun, I. S., Sergienko, V. I., & Kalinina, T. S. (2019). Calcium salt of N-(5-Hydroxynicotinoyl)-L-glutamic acid weakens depressive-like behavior and parkinsonian syndrome in experiment on rodents. Bulletin of Experimental Biology and Medicine, 168(1), 48-51. https://doi.org/10.1007/s10517-019-04643-5

Klein, A., & Schmidt, W. J. (2003). Catalepsy intensifies context-dependently irrespective of whether it is induced by intermittent or chronic dopamine deficiency. Behavioral Pharmacology, 14(1), 49-53. https://doi.org/10.1097/00008877-200302000-00005

Kobayashi, T., Araki, T., Itoyama, Y., Takeshita, M., Ohta, T., & Oshima, Y. (1997). Effects of L-DOPA and Bromocriptine on haloperidol-induced motor deficits in mice. Life Sciences, 61(26), 2529-2538. https://doi.org/10.1016/s0024-3205(97)01007-2

Konieczny, J., & Lenda, T. (2013). Contribution of the mGluR7 receptor to antiparkinsonian-like effects in rats: A behavioral study with the selective agonist AMN082. Pharmacological Reports, 5, 1194-1203. https://doi.org/10.1016/s1734-1140(13)71477-4

Konieczny, J., Ossowska, K., Schulze, G., Coper, H., & Wolfarth, S. (1999). L-701,324, a selective antagonist at the glycine site of the NMDA receptor, counteracts haloperidol-induced muscle rigidity in rats. Psychopharmacology (Berl), 143, 235-243. https://doi.org/10.1007/s002130050942

Konieczny, J., Przegalinski, E., & Pokorski, M. (2009). N-oleoyl-dopamine decreases muscle rigidity induced by reserpine in rats. International Journal of Immunopathology and Pharmacology, 22, 21-28. https://doi.org/10.1177/039463200902200104

Konieczny, J., Wardas, J., Kuter, K., Pilc, A., & Ossowska, K. (2007). The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane -1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats. Neuroscience, 145(2), 611-620. https://doi.org/10.1016/j.neuroscience.2006.12.006

Koranda, J. L., Krok, A. C., Xu, J., Contractor, A., McGehee, D. S., Beeler, J. A., & Zhuang, X. (2016). Chronic nicotine mitigates aberrant inhibitory motor learning induced by motor experience under dopamine deficiency. Journal of Neuroscience, 36(19), 5228-5240. https://doi.org/10.1523/JNEUROSCI.2754-15.2016

Kretschmer, B. D. (1994). Felbamate, an anti-convulsive drug, has anti-parkinsonian potential in rats. Neuroscience Letters, 179(1-2), 115-118. https://doi.org/10.1016/0304-3940(94)90948-2

Kretschmer, B. D., Kratzer, U., Breithecker, K., & Koch, M. (1997). ACEA 1021, a glycine site antagonist with minor psychotomimetic and amnestic effects in rats. European Journal of Pharmacology, 331(2-3), 109-116. https://doi.org/10.1016/s0014-2999(97)01047-9

Kretschmer, B. D., Winterscheid, B., Danysz, W., & Schmidt, W. J. (1994). Glycine site antagonists abolish dopamine D2 but not D1 receptor mediated catalepsy in rats. Journal of Neural Transmission, 95(2), 123-136. https://doi.org/10.1007/BF01276431

Kronbauer, M., Metz, V. G., Roversi, K., Dias, V. T., de David Antoniazzi, C. T., da Silva Barcelos, R. C., & Burger, M. E. (2017). Influence of magnesium supplementation on movement side effects related to typical antipsychotic treatment in rats. Behavioural Brain Research, 320, 400-411. https://doi.org/10.1016/j.bbr.2016.10.049

Kulkarni, S. K., Bishnoi, M., & Chopra, K. (2009). In vivo microdialysis studies of striatal level of neurotransmitters after haloperidol and chlorpromazine administration. Indian Journal of Experimental Biology, 47(2), 91-97. https://pubmed.ncbi.nlm.nih.gov/19374163/

Kumar, A., & Kulkarni, S. K. (2006). Effect of BR-16A (Mentat®), a polyherbal formulation on drug-induced catalepsy in mice. Indian Journal of Experimental Biology, 44(1), 45-48. https://pubmed.ncbi.nlm.nih.gov/16430090/

Kumar, S., Ali, J., & Baboota, S. (2016). Design Expert (®) supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson’s disease. Nanotechnology, 27(43), 435101. https://doi.org/10.1088/0957-4484/27/43/435101

Kumari, N., Agrawal, S., & Luthra, P. M. (2017). Pharmacological assessments of potent A 2A receptor antagonist IDPU (1-(7-imino-3-propyl-2,3-dihydrothiazolo [4,5-d]pyrimidin-6(7H) -yl)urea) in rodent model of haloperidol induced Parkinson like symptoms. Neuroscience Letters, 647, 53-60. https://doi.org/10.1016/j.neulet.2017.03.033

Kumari, N., Mishra, C. B., Prakash, A., Kumar, N., Mongre, R., & Luthra, P. M. (2014). 8-(Furan-2-yl)-3-phenethylthiazolo[5,4-e][1,2,4]triazolo[1,5-c]pyrimidine-2(3H)-thione as novel, selective and potent adenosine A2A receptor antagonist. Neuroscience Letters, 558, 203-207. https://doi.org/10.1016/j.neulet.2013.10.035

Łażewska, D., Olejarz-Maciej, A., Reiner, D., Kaleta, M., Latacz, G., Zygmunt, M., Doroz-Płonka, A., Karcz, T., Frank, A., Stark, H., & Kieć-Kononowicz, K. (2020). Dual target ligands with 4-tert-butylphenoxy scaffold as histamine H3 receptor antagonists and monoamine oxidase B inhibitors. International Journal of Molecular Sciences, 21(10), 3411. https://doi.org/10.3390/ijms21103411

Lazzarini, M., Salum, C., & Del Bel, E. A. (2005). Combined treatment of ascorbic acid or alpha-tocopherol with dopamine receptor antagonist or nitric oxide synthase inhibitor potentiates cataleptic effect in mice. Psychopharmacology (Berl), 181(1), 71-79. https://doi.org/10.1007/s00213-005-2222-6

Le Poul, E., Boléa, C., Girard, F., Poli, S., Charvin, D., Campo, B., Bortoli, J., Bessif, A., Luo, B., Koser, A. J., Hodge, L. M., Smith, K. M., DiLella, A. G., Liverton, N., Hess, F., Browne, S. E., & Reynolds, I. J. (2012). A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson’s disease. Journal of Pharmacology and Experimental Therapeutics, 343(1), 167-177. https://doi.org/10.1124/jpet.112.196063

Lebsanft, H. B., Kohles, T., Kovar, K. A., & Schmidt, W. J. (2005). 3,4-Methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat rotational behavior and catalepsy. Synapse (New York, N. Y.), 55(3), 148-155. https://doi.org/10.1002/syn.20102

Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ, 339, b2700. https://doi.org/10.1136/bmj.b2700

Lopez, S., Jouve, L., Turle-Lorenzo, N., Goff, L. K. L., Salin, P., & Amalric, M. (2012). Antiparkinsonian action of a selective group III mGlu receptor agonist is associated with reversal of subthalamonigral overactivity. Neurobiology of Disease, 46(1), 69-77. https://doi.org/10.1016/j.nbd.2011.12.045

Lopez, S., Turle-Lorenzo, N., Acher, F., Leonibus, E., Mele, A., & Amalric, M. (2007). Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson's disease. The Journal of Neuroscience, 27(25), 6701-6711. https://doi.org/10.1523/JNEUROSCI.0299-07.2007

Lopez, S., Turle-Lorenzo, N., Johnston, T. H., Brotchie, J. M., Schann, S., Neuville, P., & Amalric, M. (2008). Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats. Neuropharmacology, 55(4), 483-490. https://doi.org/10.1016/j.neuropharm.2008.06.038

Lorenc-Koci, E., Wolfarth, S., & Ossowska, K. (1996). Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity. Experimental Brain Research, 109, 268-276. https://doi.org/10.1007/BF00231786

Lotharius, J., & Brundin, P. (2002). Pathogenesis of Parkinson's disease: Dopamine, vesicles and alpha-synuclein. Nature Reviews Neuroscience, 3(12), 932-942. https://doi.org/10.1038/nrn983

Luthra, P. M., Barodia, S. K., & Raghubir, R. (2008). Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: A pre-clinical model to study Parkinson’s disease. Journal of Neuroscience Methods, 178(2), 284-290. https://doi.org/10.1016/j.jneumeth.2008.12.019

Luthra, P. M., Prakash, A., Barodia, S. K., Kumari, R., Mishra, C. B., & Kumar, J. B. S. (2009). In silico study of naphtha [1, 2-d] thiazol-2-amine with adenosine A2A receptor and its role in antagonism of haloperidol-induced motor impairments in mice. Neuroscience Letters, 463(3), 215-218. https://doi.org/10.1016/j.neulet.2009.07.085

Lyles-Eggleston, M., Altundas, R., Xia, J., Sikazwe, D. M. N., Fan, P., Yang, Q., Li, S., Zhang, W., Zhu, X., Schmidt, A. W., Vanase-Frawley, M., Shrihkande, A., Villalobos, A., Borne, R. F., & Ablordeppey, S. Y. (2004). Design, synthesis, and evaluation of metabolism-based analogues of haloperidol incapable of forming MPP+-like species. Journal of Medicinal Chemistry, 47(3), 497-508. https://doi.org/10.1021/jm0301033

Mabrouk, O. S., Marti, M., & Morari, M. (2010). Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: A combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice. Neuroscience, 166(1), 40-48. https://doi.org/10.1016/j.neuroscience.2009.12.006

Maj, J., Rogóz, Z., & Skuza, G. (1999). The anticataleptic effect of 7-OH-DPAT: Are dopamine D3 receptors involved? Journal of Neural Transmisson, 106, 1063-1073. https://doi.org/10.1007/s007020050223

Maj, J., Rogóż, Z., Skuza, G., Sowińska, H., & Superata, J. (1990). Behavioural and neurochemical effects of Ro 40-7592, a new COMT inhibitor with a potential therapeutic activity in Parkinson’s disease. Journal of Neural Transmission: Parkinson's Disease a and Dementia Section, 2(2), 101-112. https://doi.org/10.1007/BF02260898

Makhija, D., & Jagtap, A. (2014). Studies on sensitivity of zebrafish as a model organism for Parkinson′s disease: Comparison with rat model. Journal of Pharmacology and Pharmacotherapeutics, 5(1), 39-46. https://doi.org/10.4103/0976-500x.124422

Mandhane, S. N., Chopde, C. T., & Ghosh, A. K. (1997). Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats. European Journal Pharmacology, 328(2-3), 135-141. https://doi.org/10.1016/s0014-2999(97)83039-7

Manikandaselvi, S., Mahalakshmi, R., Thinagarbabu, R., & Angumeenal, A. R. (2012). Neuroprotective activity of S-Allylcysteine on Haloperidol induced Parkinson’s disease in albino mice. International Journal of PharmTech Research, 4(2), 669-675.

Marazziti, D., Mandillo, S., Di Pietro, C., Golini, E., Matteoni, R., & Tocchini-Valentini, G. P. (2007). GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs. Proceedings of the National Academy of Sciences of the United States of America, 104(23), 9846-9851. https://doi.org/10.1073/pnas.0703368104

Marchese, G., Bartholini, F., Casu, M. A., Ruiu, S., Casti, P., Congeddu, E., Tambaro, S., & Pani, L. (2004). Haloperidol versus risperidone on rat “early onset” vacuous chewing. Behavioral Brain Research, 149(1), 9-16. https://doi.org/10.1016/s0166-4328(03)00192-x

Markou, A., Chiamulera, C., Geyer, M. A., Tricklebank, M., & Steckler, T. (2009). Removing obstacles in neuroscience drug discovery: The future path for animal models. Neuropsychopharmacology, 34(1), 74-89. https://doi.org/10.1038/npp.2008.173

Marti, M., Mela, F., Guerrini, R., Calò, G., Bianchi, C., & Morari, M. (2004). Rapid communication: Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release: Blockade of NOP receptors reverses catalepsy. Journal of Neurochemistry, 91(6), 1501-1504. https://doi.org/10.1111/j.1471-4159.2004.02843.x

Matsui, A., Matsuo, H., Takanaga, H., Sasaki, S., Maeda, M., & Sawada, Y. (1998). Prediction of catalepsies induced by amiodarone, aprindine and procaine: Similarity in conformation of diethylaminoethyl side chain. Journal of Pharmacology and Experimental Therapeutics, 287(2), 725-732. https://jpet.aspetjournals.org/content/287/2/725.long.

Matsuo, H., Matsui, A., Nasu, R., Takanaga, H., Inoue, N., Hattori, F., Ohtani, H., & Sawada, Y. (2000). Propiverine-induced parkinsonism: A case report and a pharmacokinetic/pharmacodynamic study in mice. Pharmaceutical Research, 17(5), 565-571. https://doi.org/10.1023/a:1007516916077

Maurice, N., Deltheil, T., Melon, C., Degos, B., Mourre, C., Amalric, M., & Goff, L. K. L. (2015). Bee venom alleviates motor deficits and modulates the transfer of cortical information through the basal ganglia in rat models of Parkinson’s disease. PLoS One, 10(11), e0142838.

McAllister, K. H. (1996). The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats. European Journal of Pharmacology, 314(3), 307-311. https://doi.org/10.1016/s0014-2999(96)00576-6

Mehta, A. K., & Ticku, M. K. (1990). Role of N-methyl-d-aspartate (NMDA) receptors in experimental catalepsy in rats. Life Science, 46(1), 37-42. https://doi.org/10.1016/0024-3205(90)90054-u

Meissner, W. G., Frasier, M., Gasser, T., Goetz, C. G., Lozano, A., Piccini, P., Obeso, J. A., Rascol, O., Schapira, V., Voon, V., Weiner, D. M., Tison, F., & Bezard, E. (2011). Priorities in Parkinson’s disease research. Nature Reviews Drug Discovery, 10(5), 377-393. https://doi.org/10.1038/nrd3430

Melo, L. L., Santos, P., Medeiros, P., Mello, R. O., Ferrari, E. A. M., Brandão, M. L., Maisonnette, S. S., Francisco, A., & Coimbra, N. C. (2010). Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy. Brain Research, 19(1349), 41-47. https://doi.org/10.1016/j.brainres.2010.06.020

Melo-Thomas, L., & Thomas, U. (2015). Deep brain stimulation of the inferior colliculus: A possible animal model to study paradoxical kinesia observed in some parkinsonian patients? Behavioural Brain Research, 279, 1-8. https://doi.org/10.1016/j.bbr.2014.10.035

Mhyre, T. R., Boyd, J. T., Hamill, R. W., & Maguire-Zeiss, K. A. (2012). Parkinson’s disease. Subcellular Biochemistry, 65, 389-455. https://doi.org/10.1007/978-94-007-5416-4_16

Mihara, T., Mihara, K., Yarimizu, J., Mitani, Y., Matsuda, R., Yamamoto, H., Aoki, S., Akahane, A., Iwashita, A., & Matsuoka, N. (2007). Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-Amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one(ASP5854), in models of Parkinson's disease and cognition. Journal of Pharmacology and Experimental Therapeutics, 323(2), 708-719. https://doi.org/10.1124/jpet.107.121962

Miksys, S., Wadji, F. B., Tolledo, E. C., Remington, G., Nobrega, J. N., & Tyndale, R. F. (2017). Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side-effects by different mechanisms. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 78(1), 140-148. https://doi.org/10.1016/j.pnpbp.2017.04.030

Mishra, C. B., Barodia, S. K., Prakash, A., Kumar, J. B. S., & Luthra, P. M. (2010). Novel 8-(furan-2-yl)-3-substituted thiazolo [5,4-e][1,2,4] triazolo[1,5-c] pyrimidine-2(3H)-thione derivatives as potential adenosine A2A receptor antagonists. Bioorganic & Medicinal Chemistry, 18(7), 2491-2500. https://doi.org/10.1016/j.bmc.2010.02.048

Miwa, H., Fuwa, T., Yokochi, M., Nishi, K., & Mizuno, Y. (1996). Injection of a GABA antagonist into the mesopontine reticular formation abolishes haloperidol induced catalepsy in rats. NeuroReport, 7(15-17), 2475-2478. https://doi.org/10.1097/00001756-199611040-00014

Mograbi, K. D. M., de Castro, A. C. F., de Oliveira, J. A. R., Sales, P. J. B., Covolan, L., Del Bel, E. A., & de Souza, A. S. (2017). Effects of GABAa receptor antagonists on motor behavior in pharmacological Parkinson’s disease model in mice. Physiological Reports, 5(6), 1-8. https://doi.org/10.14814/phy2.13081

Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Journal of Clinical Epidemiology, 62(10), 1006-1012. https://doi.org/10.1016/j.jclinepi.2009.06.005

Moo-Puc, R. E., Góngora-Alfaro, J. L., Alvarez-Cervera, F. J., Pineda, J. C., Arankowsky-Sandoval, G., & Heredia-López, F. (2003). Caffeine and muscarinic antagonists act in synergy to inhibit haloperidol-induced catalepsy. Neuropharmacology, 45(4), 493-503. https://doi.org/10.1016/s0028-3908(03)00202-8

Moore, N. A., Blackman, A., Awere, S., & Leander, J. D. (1993). NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists. European Journal of Pharmacology, 237(1), 1-7. https://doi.org/10.1016/0014-2999(93)90085-v

Morelli, M., & Di Chiara, G. (1985). Catalepsy induced by SCH 23390 in rats. European Journal of Pharmacology, 117, 179-185. https://doi.org/10.1016/0014-2999(85)90602-8

Muticã, M., Marinescu, I., Militaru, F., Pîrlog, M. C., & Udristoiu, I. (2016). Clinical and biological outcomes of prolonged treatment with haloperidol in schizophrenia. Romanian Journal of Morphology Embryology, 57(2), 477-481.

Nade, V. S., Kawale, L. A., Zambre, S. S., & Kapure, A. B. (2015). Neuroprotective potential of Beta vulgaris L. in Parkinson′s disease. Indian Journal of Pharmacology, 47(4), 403-408. https://doi.org/10.4103/0253-7613.161263

Nasu, R., Matsuo, H., Takanaga, H., Ohtani, H., & Sawada, Y. (2000). Quantitative prediction of catalepsy induced by amoxapine, cinnarizine and cyclophosphamide in mice. Biopharmaceutics & Drug Disposition, 21(4), 129-138. https://doi.org/10.1002/1099-081x(200005)21:4<129:aid-bdd224>3.0.co;2-f

Nayebi, M. A., & Sheidaei, H. (2010). Buspirone improves haloperidol-induced Parkinson disease in mice through 5-HT1A receptors. Daru Journal of Pharmaceutical Sciences, 18(1), 41-45.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232083/pdf/DARU-18-041.pdf.

Neustadt, B. R., Hao, J., Lindo, N., Greenlee, W. J., Stamford, A. W., Tulshian, D., Ongini, E., Hunter, J., Monopoli, A., Bertorelli, R., Foster, C., Arik, L., Lachowicz, J., Nga, K., & Feng, K. I. (2007). Potent, selective, and orally active adenosine A2A receptor antagonists: Arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines. Bioorganic & Medicinal Chemistry Letters, 17(5), 1376-1380. https://doi.org/10.1016/j.bmcl.2006.11.083

Neustadt, B. R., Liu, H., Hao, J., Greenlee, J. W., Stamford, A. W., Foster, C., Arik, L., Lachowicz, J., Zhang, H., Bertorelli, R., Fredduzzi, S., Varty, G., Cohen-Williams, M., & Ng, K. (2009). Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines. Bioorganic & Medicinal Chemistry Letters, 19(3), 967-971. https://doi.org/10.1016/j.bmcl.2008.11.075

Neves, G., Fenner, R., Heckler, A. P., Viana, A. F., Tasso, L., Menegatti, R., Fraga, C. A. M., Barreiro, E. J., Dalla-Costa, T., & Rates, S. M. K. (2003). Dopaminergic profile of new heterocyclic N-phenylpiperazine derivatives. Brazilian Journal of Medical and Biological Research, 36(5), 625-629. https://doi.org/10.1590/S0100-879X2003000500010

Niswender, C. M., Johnson, K. A., Weaver, C. D., Jones, C. K., Xiang, Z., Luo, Q., Rodriguez, A. L., Marlo, J. E., de Paulis, T., Thompson, A. D., Days, E. L., Nalywajko, T., Austin, C. A., Williams, M. B., Ayala, J. E., Williams, R., Lindsley, C. W., & Conn, P. J. (2008). Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor. Molecular Pharmacology, 74(5), 1345-1358. https://doi.org/10.1124/mol.108.049551

Niswender, C. M., Jones, C. K., Lin, X., Bubser, M., Gray, A. T., Blobaum, A. L., Engers, D. W., Rodriguez, A. L., Loch, M. T., Daniels, J. S., Lindsley, C. W., Hopkins, C. R., Javitch, J. A., & Conn, P. J. (2016). Development and antiparkinsonian activity of VU0418506, a selective positive allosteric modulator of metabotropic glutamate receptor 4 homomers without activity at mGlu2/4Heteromers. ACS Chemical Neuroscience, 7(9), 1201-1211. https://doi.org/10.1021/acschemneuro.6b00036

Nowak, P., Bojanek, K., Szkilnik, R., Josko, J., Boron, D., Adwent, M., Gorczyca, P., Kostrzewa, R. M., & Brus, R. (2010). Ontogenetic exposure of rats to pre- and post-natal manganese enhances behavioral impairments produced by perinatal 6-hydroxydopamine. Neurotoxicity Research, 19(4), 536-543. https://doi.org/10.1007/s12640-010-9184-0

Nuñez, F., Taura, J., Camacho, J., López-Cano, M., Fernández-Dueñas, V., Castro, N., Castro, J., & Ciruela, F. (2018). PBF509, an adenosine A2A receptor antagonist with efficacy in rodent models of movement disorders. Frontiers in Pharmacology, 9(1200), 9-10. https://doi.org/10.3389/fphar.2018.01200

Nurmaganbetov, Z. S., Arystan, L. I., Muldaeva, G. M., Haydargalieva, L. S., & Adekenov, S. M. (2019). Experimental study of antiparkinsonian action of the harmine hydrochloride original compound. Pharmacological Reports, 71(6), 1050-1058. https://doi.org/10.1016/j.pharep.2019.06.002

Nuutila, J., Kaakkola, S., & Mannisto, P. T. (1987). Potentiation of central effects of L-dopa by an inhibitor of catechol-O-methyltransferase. Journal of Neural Transmission, 70(3-4), 233-240. https://doi.org/10.1007/BF01253600

Olaya, M. D. P., Vergel, N. E., López, J. L., Viña, D., & Guerrero, M. F. (2020). 8-Propyl-6H-[1,3] dioxolo[4,5-g]chromen-6-one: A new coumarin with monoamine oxidase B inhibitory activity and possible anti-parkinsonian effects. Brazilian Journal of Pharmaceutical Sciences, 56, e17609. https://doi.org/10.1590/s2175-97902019000317609

Olaya, M. D. P., Vergel, N. E. A., López, J. L., Viña, M. D., & Guerrero, M. F. (2019). Coumarin analogue 3-methyl-7H-furo[3,2-g] chromen-7-one as a possible antiparkinsonian agent. Biomédica, 39(3), 491-501. https://doi.org/10.7705/biomedica.4299

Ossowska, K., Konieczny, J., Wofarth, S., Wieronska, J., & Pilc, A. (2001). Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rats. Neuropharmacology, 41(4), 413-420. https://doi.org/10.1016/s0028-3908(01)00083-1

Ossowska, K., Konieczny, J., Wolfarth, S., & Pilc, A. (2005). MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats. Neuropharmacology, 49(4), 447-455. https://doi.org/10.1016/j.neuropharm.2005.04.002

Ossowska, K., Wardas, J., Pietraszek, M., Konieczny, J., & Wolfharth, S. (2003). The striopallidal pathway is involved in antiparkinsonian-like effects of the blockade of group I metabotropic glutamate receptors in rats. Neuroscience Letters, 342(1-2), 21-24. https://doi.org/10.1016/s0304-3940(03)00221-0

Panarese, J. D., Engers, D. W., Wu, Y. J., Bronson, J. J., Macor, J. E., Chun, A., Rodriguez, A. L., Felts, A. S., Engers, J. L., Loch, M. T., Emmitte, K. A., Castelhano, A. L., Kates, M. J., Nader, M. A., Jones, C. K., Blobaum, A. L., Conn, P. J., Niswender, C. M., Hopkins, C. R., & Lindsley, C. W. (2019). Discovery of VU2957 (Valiglurax): An mGlu4 positive allosteric modulator evaluated as a preclinical candidate for the treatment of Parkinson’s disease. ACS Medicinal Chemistry Letters, 10(3), 255-260. https://doi.org/10.1021/acsmedchemlett.8b00426

Parambi, D. G. T., Saleem, U., Shah, M. A., Anwar, F., Ahmad, B., Manzar, A., Itzaz, A., Harilal, S., Uddin, S. M., Kim, H., & Mathew, B. (2020). Exploring the therapeutic potentials of highly selective oxygenated chalcone based MAO-b inhibitors in a haloperidol-induced murine model of Parkinson’s disease. Neurochemical Research, 45(11), 2786-2799. https://doi.org/10.1007/s11064-020-03130-y

Pardo, M., Paul, N. E., Collins-Praino, L. E., Salamone, J. D., & Correa, M. (2020). The non-selective adenosine antagonist theophylline reverses the effects of dopamine antagonism on tremor, motor activity and effort-based decision-making. Pharmacology Biochemistry and Behavior, 198, 173035. https://doi.org/10.1016/j.pbb.2020.173035

Parkinson, J. (2002). An essay on the shaking palsy. The Journal of Neuropsychiatry and Clinical Neurosciences, 14(2), 223-236. https://doi.org/10.1176/jnp.14.2.223

Patel, P., Pol, A., More, S., Kalaria, D. R., Kalia, Y. N., & Patravale, V. B. (2014). Colloidal soft nanocarrier for transdermal delivery of dopamine agonist: Ex vivo and in vivo evaluation. Journal of Biomedical Nanotechnology, 10(11), 3291-3303. https://doi.org/10.1166/jbn.2014.1857

Pavlova, A. V., Il’ina, I. V., Morozova, E. A., Korchagina, D. V., Yu Kurbakova, S., Sorokina, I. V., Tolstikova, T. G., Volcho, K. P., & Salakhutdinov, N. F. (2014). Potent neuroprotective activity of monoterpene derived 4-[(3aR,7aS)-1,3,3a,4,5,7a-Hexahydro-3,3,6-trimethylisobenzofuran-1-yl]-2-methoxyphe nol in MPTP mice model. Letters in Drug Design & Discovery, 11(5), 611-617. https://doi.org/10.2174/1570180811666131210000316

Pingale, T., & Prabhavalkar, K. (2015). Antiparkinsonian effects and mechanistic insights of some indigenous herbal formulations. International Journal of Pharmaceutical Sciences and Research, 24(6), 4760-4771. https://doi.org/10.13040/IJPSR.0975-8232.6(11).4760-71

Pinna, A., Volpini, R., Cristalli, G., & Morelli, M. (2005). New adenosine A2A receptor antagonists: Actions on Parkinson's disease models. European Journal of Pharmacology, 512(2-3), 157-164. https://doi.org/10.1016/j.ejphar.2005.01.057

Pires, J. G. P., Bonikovski, V., & Futuro-Neto, H. A. (2005). Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice. Brazilian Journal of Medical and Biological Research, 38, 1867-1872. https://doi.org/10.1590/S0100-879X2005001200015

Pires, J. G. P., Costa, P. G., Saraiva, F. P., Bonikovski, V., & Futuro-Neto, H. A. (2003). Gender-related differences in the effects of nitric oxide donors on neuroleptic-induced catalepsy in mice. Brazilian Journal of Medical and Biological Research, 36(2), 239-245. https://doi.org/10.1590/S0100-879X2003000200012

Poewe, W., & Mahlknecht, P. (2009). The clinical progression of Parkinson’s disease. Parkinsonism & Related Disorders, 15(4), 28-32. https://doi.org/10.1016/S1353-8020(09)70831-4

Povarnina, P. Y., Gudasheva, T. A., Vorontsova, O. N., Bondarenko, N. A., & Seredenin, S. B. (2011). Antiparkinsonian properties of a nerve growth factor dipeptide mimetic GK-2 in in vivo experiments. Bulletin of Experimental Biology and Medicine, 151(6), 690-693. https://doi.org/10.1007/s10517-011-1417-6

Pycock, C., Dawbarn, D., & O’Shaughnessy, C. (1982). Behavioural and biochemical changes following chronic administration of L-dopa to rats. European Journal of Pharmacology, 79(3-4), 201-215. https://doi.org/10.1016/0014-2999(82)90626-4

Rajput, S. K., Sharma, A. K., Meena, C. L., Pant, A. B., Jain, R., & Sharma, S. S. (2016). Effect of L-pGlu-(1-benzyl)-l-His-l-Pro-NH2 against in-vitro and in-vivo models of cerebral ischemia and associated neurological disorders. Biomedicine & Pharmacotherapy, 84, 1256-1265. https://doi.org/10.1016/j.biopha.2016.10.059

Raza, C., Anjum, R., & Shakeel, N. A. (2019). Parkinson’s disease: Mechanisms, translational models and management strategies. Life Sciences, 226, 77-90. https://doi.org/10.1016/j.lfs.2019.03.057

Reynolds, G. P. (1992). Developments in the drug treatment of schizophrenia. Trends in Pharmacological Sciences, 13, 116-121. https://doi.org/10.1016/0165-6147(92)90041-4

Riedinger, K., Kulak, A., Schmidt, W. J., & von Ameln-Mayerhofer, A. (2011). The role of NMDA and AMPA/Kainate receptors in the consolidation of catalepsy sensitization. Behavioural Brain Research, 218(1), 194-199. https://doi.org/10.1021/jm100971t

Rivara, S., Piersanti, G., Bartoccini, F., Diamantini, G., Pala, D., Riccioni, T., Stasi, M. A., Cabri, W., Borsini, F., Mor, M., Tarzia, G., & Minetti, P. (2013). Synthesis of (E)-8-(3-Chlorostyryl) caffeine analogues leading to 9-deazaxanthine derivatives as dual A2A antagonists/MAO-B inhibitors. Journal of Medicinal Chemistry, 56(3), 1247-1261. https://doi.org/10.1021/jm301686s

Robinson, S. J., Petzer, J. P., Terre’Blanche, G., Petzer, A., van der Walt, M. M., Bergh, J. J., & Lourens, A. C. U. (2015). 2-Aminopyrimidines as dual adenosine A1/A2A antagonists. European Journal of Medicinal Chemistry, 104, 177-188. https://doi.org/10.1016/j.ejmech.2015.09.035

Ross, B. M., Brooks, R. J., Lee, M., Kalasinsky, K. S., Vorce, S. P., Seeman, M., Fletcher, P. J., & Turenne, S. D. (2002). Cyclooxygenase inhibitor modulation of dopamine-related behaviours. European Journal of Pharmacology, 450(2), 141-151. https://doi.org/10.1016/S0014-2999(02)02104-0

Rukoyatkina, N. I., Gorbunova, L. V., Gmiro, V. E., & Lukomskaya, N. Y. (2003). The ability of new non-competitive glutamate receptor blockers to weaken motor disorders in animals. Neuroscience and Behavioral Physiology, 33(3), 273-278. https://doi.org/10.1023/a:1022107516333

Salari, S., & Bagheri, M. (2019). In vivo, in vitro and pharmacologic models of Parkinson's disease. Physiological Research, 68(1), 17-24. https://doi.org/10.33549/physiolres.933895

Saleem, U., Raza, Z., Anwar, F., Chaudary, Z., & Ahmad, B. (2019). Systems pharmacology based approach to investigate the in-vivo therapeutic efficacy of Albizia lebbeck (L.) in experimental model of Parkinson’s disease. BMC Complementary Medicine and Therapies, 19(1), 352. https://doi.org/10.1186/s12906-019-2772-5

Sanawar, M., Saleem, U., Anwar, F., Nazir, S., Akhtar, F. M., Ahmad, B., & Ismail, T. (2020). Investigation of anti-Parkinson activity of dicyclomine. International Journal of Neuroscience, 11, 1-14. https://doi.org/10.1080/00207454.2020.1815732

Sanberg, P. R., Bunsey, M. D., Giordano, M., & Norman, A. B. (1988). The catalepsy test: Its ups and downs. Behavioral Neuroscience, 102(5), 748-759. https://doi.org/10.1037//0735-7044.102.5.748

Schallert, T., & Teitelbaum, P. (1981). Haloperidol, catalepsy, and equilibrating functions in the rat: Antagonistic interaction of clinging and labyrinthine righting reactions. Physiology & Behavior, 27(6), 1077-1083. https://doi.org/10.1016/0031-9384(81)90373-5

Scheel-Krüger, J., & Magelund, G. (1981). GABA in the entopeduncular nucleus and the subthalamic nucleus participates in mediating dopaminergic striatal output functions. Life Sciences, 29(11), 1555-1562. https://doi.org/10.1016/0024-3205(81)90256-3

Schmidt, W. J., & Bubser, M. (1989). Anticataleptic effects of the N-methyl-D-aspartate antagonist MK-801 in rats. Pharmacology Biochemistry and Behavior, 32(3), 621-623. https://doi.org/10.1016/0091-3057(89)90007-5

Schmidt, W. J., Mayerhofer, A., Meyer, A., & Kovar, K. A. (2002). Ecstasy counteracts catalepsy in rats, an anti-parkinsonian effect? Neuroscience Letters, 330(3), 251-254. https://doi.org/10.1016/S0304-3940(02)00823-6

Schmidt, W. J., Schuster, G., Wacker, E., & Pergande, G. (1997). Antiparkinsonian and other motor effects of flupirtine alone and in combination with dopaminergic drugs. European Journal of Pharmacology, 327(1), 1-9. https://doi.org/10.1016/S0014-2999(97)89671-9

Schmidt, W. J., Tzschentke, T. M., & Kretschmer, B. D. (1999). State-dependent blockade of haloperidol-induced sensitization of catalepsy by MK-801. European Journal of Neuroscience, 11(9), 3365-3368. https://doi.org/10.1046/j.1460-9568.1999.00794.x

Schmidt, W. J., Zadow, B., Kretschmer, B. D., & Hauber, W. (1991). Anticataleptic potencies of glutamate-antagonists. Amino Acids, 1(2), 225-237. https://doi.org/10.1007/BF00806920

Sharma, A. K., Gupta, S., Patel, R. K., & Wardhan, N. (2018). Haloperidol-induced parkinsonism is attenuated by varenicline in mice. Journal of Basic and Clinical Physiology and Pharmacology, 29(4), 395-401. https://doi.org/10.1515/jbcpp-2017-0107

Sharma, S., Rabbani, S. A., Narang, J. K., Pottoo, F. H., Ali, J., Kumar, S., & Baboota, S. (2020). Role of rutin nanoemulsion in ameliorating oxidative stress: Pharmacokinetic and pharmacodynamics studies. Chemistry and Physics of Lipids, 228, 104890. https://doi.org/10.1016/j.chemphyslip.2020.104890

Shastry, C. S., Kiran, U. P., & Aswathanarayana, B. J. (2012). Effect of acute and chronic administration of the aqueous extract of Lawsonia inermis leaves on haloperidol induced catalepsy in albino mice. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 3(3), 1107-1116.

Shiozaki, S., Ichikawa, S., Nakamura, J., Kitamura, S., Yamada, K., & Kuwana, Y. (1999). Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl), 147(1), 90-95. https://doi.org/10.1007/s002130051146

Shook, B. C., Rassnick, S., Osborne, M. C., Davis, S., Westover, L., Boulet, J., Hall, D., Rupert, K. C., Heintzelman, G. R., Hansen, K., Chakravarty, D., Bullington, J. L., Russell, R., Branum, S., Wells, K. M., Damon, S., Youells, S., Li, X., Beauchamp, D. A., … Jackson, P. F. (2010). In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson’s disease. Journal of Medicinal Chemistry, 53(22), 8104-8115. https://doi.org/8104-8115.10.1021/jm100971t.

Shook, B. C., Rassnick, S., Wallace, N., Crooke, J., Ault, M., Chakravarty, D., Barbay, J. K., Wang, A., Powell, M. T., Leonard, K., Alford, V., Scannevin, R. H., Carroll, K., Lampron, L., Westover, L., Lim, H. K., Russell, R., Branum, S., Wells, K. M., … Jackson, P. F. (2012). Design and characterization of optimized adenosine A2A/A1 receptor antagonists for the treatment of Parkinson's disease. Journal of Medicinal Chemistry, 3, 1402-1417. https://doi.org/10.1021/jm201640m

Shyamjith, M., Anu, E. J., Thyagaraju, B. M., & Rao, S. N. (2012). Effect of tylophora indica on haloperidol induced catalepsy in experimental animal models. Drug Invention Today, 4(1), 652-654. http://jprsolutions.info/newfiles/journal-file-55f0fcfe32e805.36166871.pdf.

Sibille, P., Lopez, S., Brabet, I., Valenti, O., Oueslati, N., Gaven, F., Goudet, C., Bertrand, H. O., Neyton, J., Marino, M. J., Almaric, M., Pin, J. P., & Acher, F. C. (2007). Synthesis and biological evaluation of 1-Amino-2-Phosphonomethylcyclopropanecarboxylic acids. New Group III Metabotropic Glutamate Receptor Agonists. Journal of Medicinal Chemistry, 50(15), 3585-3595. https://doi.org/10.1021/jm070262c

Sinnathambi, A., Mazumder, P. M., Lohidasan, S., & Thakurdesai, P. (2013). Dopaminergic effect of Alstonia scholaris Linn. R.Br. in experimentally induced anxiety. Biomedicine & Aging Pathology, 3(2), 51-57.

Sita, V. G., Jadhav, D., & Vavia, P. (2020). Niosomes for nose-to-brain delivery of bromocriptine: Formulation development, efficacy evaluation and toxicity profiling. Journal of Drug Delivery Science and Technology, 58, 101791. https://doi.org/10.1016/j.jddst.2020.101791

Slee, D. H., Zhang, X., Moorjani, M., Lin, E., Lanier, M. C., Chen, Y., Rueter, J. K., Lechner, S. M., Markison, S., Malany, S., Joswig, T., Santos, M., Gross, R. S., Williams, J. P., Palomino, J. C. C., Crespo, M. I., Prat, M., Gual, S., Díaz, J. L., … Saunders, J. (2008). Identification of novel, water-soluble, 2-Amino-N-pyrimidin-4-yl acetamides as A2AReceptor antagonists with in vivo efficacy. Journal of Medicinal Chemistry, 51(3), 400-406.

Srinivasan, J., & Schmidt, W. J. (2003a). Intensification of cataleptic response in 6-hydroxydopamine-induced neurodegeneration of substantia nigra is not dependent on the degree of dopamine depletion. Synapse (New York, N. Y.), 51(3), 213-218. https://doi.org/10.1002/syn.10297

Srinivasan, J., & Schmidt, W. J. (2003b). Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. European Journal of Neuroscience, 17(12), 2586-2592. https://doi.org/10.1046/j.1460-9568.2003.02684.x

Srinivasan, J., & Schmidt, W. J. (2004). Functional recovery of locus coeruleus noradrenergic neurons after DSP-4 lesion: Effects on dopamine levels and neuroleptic induced-parkinsonian symptoms in rats. Journal of Neural Transmission, 111(1), 13-26. https://doi.org/10.1007/s00702-003-0062-2

Stasi, M. A., Borsini, F., Varani, K., Vincenzi, F., Di Cesare, M. A., Minetti, P., Ghirardi, O., & Carminati, P. (2006). ST 1535: A preferential A2A adenosine receptor antagonist. International Journal of Neuropsychopharmacology, 9(5), 575-584. https://doi.org/10.1017/S1461145705006188

Stasi, M. A., Minetti, P., Lombardo, K., Riccioni, T., Caprioli, A., Vertechy, M., Di Serio, S., Pace, S., & Borsini, F. (2015). Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2 n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535). European Journal of Pharmacology, 761, 353-361. https://doi.org/10.1016/j.ejphar.2015.03.070

Steece-Collier, K., Chambers, L. K., Jaw-Tsai, F. S., Menniti, S. S., & Greenamyre, J. T. (2000). Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-Methyl-d-aspartate receptors. Experimental Neurology, 163(1), 239-243. https://doi.org/10.1006/exnr.2000.7374

Striem, S., Bar-Joseph, A., Berkovitch, Y., & Biegon, A. (1997). Interaction of dexanabinol (HU-211), a novel NMDA receptor antagonist, with the dopaminergic system. European Journal of Pharmacology, 338(3), 205-213. https://doi.org/10.1016/S0014-2999(97)81923-1

Tamilanban, T., Manasa, K., Raju, D., & Chitra, V. (2015). Effect of methanolic extract of canscora decussate on haloperidol-induced motor deficits in albino mice. International Journal of Pharmaceutical Sciences Review and Research, 35(1), 7-11.https://globalresearchonline.net/journalcontents/v35-1/02.pdf.

Tanganelli, S., Nielsen, K. S., Ferraro, L., Antonelli, T., Kehr, J., Franco, R., Ferré, S., Agnati, L. F., Fuxe, K., & Scheel-Kruger, J. (2004). Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease. Parkinsonism & Related Disorders, 10(5), 273-280. https://doi.org/10.1016/j.parkreldis.2004.02.015

Taura, J., Nolen, E. G., Cabré, G., Hernando, J., Squarcialupi, L., López-Cano, M., Jacobson, K. A., Fernández-Dueñas, V., & Ciruela, F. (2018). Remote control of movement disorders using a photoactive adenosine A2A receptor antagonist. Journal of Controlled Release, 283, 135-142. https://doi.org/10.1016/j.jconrel.2018.05.033

Taura, J., Valle-León, M., Sahlholm, K., Watanabe, M., Craenenbroeck, K., Craenenbroeck, K. V., Fernández-Dueñas, V., Ferré, S., & Ciruela, F. (2017). Behavioral control by striatal A2A-dopamine D2 receptor heteromers. Genes Brain and Behavior, 17(4), e12432. https://doi.org/10.1111/gbb.12432

Tian, S., Wang, X., Li, L., Zhang, X., Li, Y., Zhu, F., Hou, T., & Zhen, X. (2017). Discovery of novel and selective adenosine A2AReceptor antagonists for treating Parkinson’s Disease through comparative structure-based virtual screening. Journal of Chemical Information and Modeling, 57(6), 1474-1487. https://doi.org/10.1021/acs.jcim.7b00188

Tonelli, L. C., Wohr, M., Schwarting, R., & Melo-Thomas, L. (2017). Awakenings in rats by ultrasounds: A new animal model for paradoxical kinesia. Behavioural Brain Research, 337, 204-209. https://doi.org/10.1016/j.bbr.2017.09.021

Tonelli, L. C., Wohr, M., Schwarting, R., & Melo-Thomas, L. (2018). Paradoxical kinesia induced by appetitive 50-kHz ultrasonic vocalizations in rats depends on glutamatergic mechanisms in the inferior colliculus. Neuropharmacology, 135, 172-179. https://doi.org/10.1016/j.neuropharm.2018.03.013

Trevitt, J., Vallance, C., Harris, A., & Goode, T. (2009). Adenosine antagonists reverse the cataleptic effects of haloperidol: Implications for the treatment of Parkinson’s disease. Pharmacology, Biochemistry, Behavior, 92(3), 521-527. https://doi.org/10.1016/j.pbb.2009.02.001

Trevizol, F., Benvegnú, D. M., Barcelos, R. C. S., Pase, C. S., Segat, H. J., Dias, V. T., Dolci, G. S., Boufleur, N., Reckziegel, P., & Bürger, M. E. (2011). Comparative study between two animal models of extrapyramidal movement disorders: Prevention and reversion by pecan nut shell aqueous extract. Behavioural Brain Research, 221(1), 13-18. https://doi.org/10.1016/j.bbr.2011.02.026

Tsujikawa, K., Dan, Y., Nogawa, K., Sato, H., Yamada, Y., Murakami, H., Ohtani, H., Sawada, Y., & Iga, T. (2003). Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A. Biopharmaceutics & Drug Disposition, 24(3), 105-114. https://doi.org/10.1002/bdd.343

Tysnes, O. B., & Storstein, A. (2017). Epidemiology of Parkinson’s disease. Journal of Neural Transmission, 124(8), 901-905. https://doi.org/10.1007/s00702-017-1686-y

Valdman, E., Kapitsa, I., Ivanova, E., Voronina, T., Ardashov, O., Volcho, K., Khazanov, V., & Salakhutdinov, N. (2017). Evolution of anti-parkinsonian activity of monoterpenoid (1R,2R, 6S)-3-methyl-6-(prop-1-en-2-yl)cyclohex-3-ene-1,2-diol in various in vivo models. European Journal of Pharmacology, 815, 351-363. https://doi.org/10.1016/j.ejphar.2017.09.022

Van der Walt, M. M., Terre’Blanche, G., Petzer, A., Lourens, A. C. U., & Petzer, J. P. (2013). The adenosine A2A antagonistic properties of selected C8-substituted xanthines. Bioorganic & Medicinal Chemistry, 49, 49-58. https://doi.org/10.1016/j.bioorg.2013.06.006

Verhagen-Kamerbeek, W. D. J., Hazemeijer, I., Korf, J., & Lakke, J. P. W. F. (1993). Attenuation of haloperidol-induced catalepsy by noradrenaline and L-threo-DOPS. Journal of Neural Transmission, 6, 17-26. https://doi.org/10.1007/BF02252619

Vetulani, J., Antkiewicz-Michaluk, L., Nalepa, I., & Sansone, M. (2003). A possible physiological role for cerebral tetrahydroisoquinolines. Neurotoxicity Research, 5, 147-155. https://doi.org/10.1007/BF03033379

Villanueva-Toledo, J., Moo-Puc, R. E., & Góngora-Alfaro, J. L. (2003). Selective A2A, but not A1 adenosine antagonists enhance the anticataleptic action of trihexyphenidyl in rats. Neuroscience Letters, 346(1-2), 1-4. https://doi.org/10.1016/s0304-3940(03)00337-9

Wadenberg, M. L. G., Soliman, A., VanderSpek, S. C., & Kapur, S. (2001). Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology, 25, 633-641. https://doi.org/10.1016/S0893-133X(01)00261-5

Wang, S., Hu, L. F., Yang, Y., Ding, J. H., & Hu, G. (2005). Studies of ATP-sensitive potassium channels on 6-hydroxydopamine and haloperidol rat models of Parkinson’s disease: Implications for treating Parkinson’s disease? Neuropharmacology, 48(7), 984-992. https://doi.org/10.1016/j.neuropharm.2005.01.009

Wang, X., Han, C., Xu, Y., Wu, K., Chen, S., Hu, M., Wang, L., Ye, Y., & Ye, F. (2017). Synthesis and evaluation of phenylxanthine derivatives as potential dual A2AR antagonists/MAO-B inhibitors for Parkinson’s disease. Molecules, 22(6), 1010. https://doi.org/10.3390/molecules22061010

Wang, Y., Xu, R., Sasaoka, T., Tonegawa, S., Kung, M. P., & Sankoorikal, E. B. (2000). Dopamine D2 long receptor-deficient mice display alterations in striatum-dependent functions. The Journal of Neuroscience, 20, 8305-8314. https://doi.org/10.1523/JNEUROSCI.20-22-08305.2000

Wardas, J., Pietraszek, M., & Dziedzicka-Wasylewska, M. (2003). SCH 58261, a selective adenosine A2A receptor antagonist, decreases the haloperidol-enhanced proenkephalin mRNA expression in the rat striatum. Brain Research, 977(2), 270-277. https://doi.org/10.1016/s0006-8993(03)02759-8

Weihmuller, F. B., Hadjiconstantinou, M., & Bruno, J. P. (1988a). Acute stress or neuroleptics elicit sensorimotor deficits in MPTP-treated mice. Neuroscience Letters, 85(1), 137-142. https://doi.org/10.1016/0304-3940(88)90443-0

Weihmuller, F. B., Hadjiconstantinou, M., Bruno, J. P., & Neff, N. H. (1988b). Administration of GM1 ganglioside eliminates neuroleptic-induced sensorimotor deficits in MPTP-treated mice. Neuroscience Letters, 92(2), 207-212. https://doi.org/10.1016/0304-3940(88)90062-6

Weihmuller, F. B., Hadjiconstantinou, M., Bruno, J. P., & Neff, N. H. (1989). Continued administration of GM1 ganglioside is required to maintain recovery from neuroleptic-induced sensorimotor deficits in MPTP-treated mice. Life Sciences, 45(25), 2495-2502. https://doi.org/10.1016/0024-3205(89)90017-9

Willner, P. (1984). The validity of animal models of depression. Psychopharmacology (Berl), 83(1), 1-16. https://doi.org/10.1007/BF00427414

Xiang, Z., Thompson, A. D., Jones, C. K., Lindsley, C. W., & Conn, P. J. (2012). Roles of the M1 muscarinic acetylcholine receptor subtype in the regulation of basal ganglia function and implications for the treatment of Parkinson’s Disease. Journal of Pharmacology and Experimental Therapeutics, 340(3), 595-603. https://doi.org/10.1124/jpet.111.187856

Xu, R., Hranilovic, D., Fetsko, L. A., Bucan, M., & Wang, Y. (2002). Dopamine D2S and D2L receptors may differentially contribute to the actions of antipsychotic and psychotic agents in mice. Molecular Psychiatry, 7, 1075-1082. https://doi.org/10.1038/sj.mp.4001145

Xue, Y., & Chen, L. (2010). Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: Behavioral and electrophysiological studies. Neuroscience Bulletin, 26(5), 345-354. https://doi.org/10.1007/s12264-010-0518-y

Yang, Z., Li, L., Zheng, J., Ma, H., Tian, S., Li, J., Zhang, H., Zhen, X., & Zhang, X. (2016). Identification of a new series of potent adenosine A2A receptor antagonists based on 4-Amino-5-carbonitrile pyrimidine template for the treatment of Parkinson’s disease. ACS Chemical Neuroscience, 7(11), 1575-1584. https://doi.org/10.1021/acschemneuro.6b00218

Zadow, B., & Schmidt, W. J. (1994). Lesions of the entopeduncular nucleus and the subthalamic nucleus reduce dopamine receptor antagonist-induced catalepsy in the rat. Behavioural Brain Research, 62(1), 71-79. https://doi.org/10.1016/0166-4328(94)90039-6

Zazpe, A., Artaiz, I., Innerárity, A., del Olmo, E., Castro, E., Labeaga, L., Pazos, A., & Orjales, A. (2006). In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties. Neuropharmacology, 51(1), 129-140. https://doi.org/10.1016/j.neuropharm.2006.03.008

Zhang, X., Rueter, J. K., Chen, Y., Moorjani, M., Lanier, M. C., Lin, E., Gross, R. S., Tellew, J. E., Williams, J. P., Lechner, S. M., Markison, S., Joswig, T., Malany, S., Santos, M., Castro-Palomino, J. C., Crespo, M. I., Prat, M., Gual, S., Dıaz, J. L., … Slee, D. H. (2008). Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists. Bioorganic & Medicinal Chemistry Letters, 18(6), 1778-1783. https://doi.org/10.1016/j.bmcl.2008.02.032

Zheng, J., Yang, Z., Li, X., Li, L., Ma, H., Wang, M., Zhang, H., Zhen, X., & Zhang, X. (2014). Optimization of 6-heterocyclic-2-(1H-pyrazol-1-yl)-N-(pyridin-2-yl)pyrimidin-4-amine as potent adenosine A2AReceptor antagonists for the treatment of Parkinson’s disease. ACS Chemical Neuroscience, 5(8), 674-682. https://doi.org/10.1021/cn5000716

Zolbanin, N. M., Zolali, E., & Nayebi, A. M. (2014). Testosterone replacement attenuates haloperidol-induced catalepsy in male rats. Advanced Pharmaceutical Bulletin, 4(3), 237-241. https://doi.org/10.5681/apb.2014.034

Haloperidol-induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies.

Journal

Informations de publication

Résumé

Identifiants

Substances chimiques

Types de publication

Langues

Sous-ensembles de citation

Pagination

Informations de copyright

Références

Auteurs

Isabelle Waku (I)

Mylena S Magalhães (MS)

Camila O Alves (CO)

Amanda R de Oliveira (AR)

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Odour generalisation and detection dog training.

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Classifications MeSH